London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: BertieBassett, 14 Jun 2024 09:13
Last post: xviolet, Today 20:12
I don't think it is meddling. I'm probably wrong but I thought the actions of the BOD were designed to raise money for the company. I think what is frustrating is the combination of that fundraising but, as some have suggested, the company not sharing all of their sales results and a more detailed business plan. There might be a good reason for the amount of information disclosed to date - perhaps in many ways this is still an early stages company. Anyway there have been some interesting RNS's recently.
Personally I'm torn between selling a percentage of my holding to have some cash ready to buy shares if/when they do a raise or just go with the flow AND make sure I have some cash ready to buy shares if/when they do a raise.
I think its really telling that we have had an average of an RNS a week for past 6wks that last year would have had us up between 4-5p region and yet whatever good news the incredible IB team keep delivering, our Master of Ceremony can't get the share price to increase past the 1.5p option price because of his meddling.
Https://x.com/IQAI_IB/status/1801654631870677003
Excellent expert discussion about the advantages of DSC perfusion imaging for brain tumors (diagnosis, grading, guiding biopsy, treatment planning, follow-up, etc)! Features exclusive to IB Software (IB Neuro) were highlighted!
@Applied_Rad
@TheASNR
Thoughts?
they keep us guessing. where's the money gonna from?
we don't know. as usual.
investing in the fog with only our faith in the company and its beloved BOD to guide us.
conviction/ faith.... its an interesting take on things?
I think people are missing the point of what IB are achieving and getting side tracked by all the BOD shenanigans. JC, KS, MS are all doing everything they set out to do. We have the FDA guiding us and why would they do that unless they saw potential.
Just my thoughts
Thanks
Started: maximillion69, 13 Jun 2024 11:14
Last post: maximillion69, 14 Jun 2024 11:44
If you watch the video on the GBM Agile trial here https://virtualtrials.org/video2024.cfm?video=202404 , at minute 47 they talk about costs. Due to the AGILE trial design, they have managed to reduce costs for participating companies to around 1/3 of normal ph2 costs. There are Glioblastoma trials that have been fully funded by the NIH. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT).
hi cautious indeed when we get line of sight to royalties which i would have expected from ib by now and the eap which i am not sure will be that material but open minded then the dynamic changes.
the fda will need to agree the trial scope as well.
but at the moment the clinical progress is being lost in the financial obscurities.
the trial isn’t due to start until into next year. that’s more cash.
it would really help if the bod put a business plan on their website so investors can see it. at the moment everything is evolving on a *** packet! they basically spend, run out of cash, tb picks up more cheap options! then repeat.
atm there is nothing to change that pattern.
no hurry to add stock here!
it could be that this times nicely to sell some hex and buy back in here end of next year. that would be a twist!
good luck
usual caveats
trek
Trek, wild assumptions are not usually your style. Suggest you check average Phase One costs from the same source, and then compare and contrast with IQAI’s Phase One costs, also note the intended number of participants on the Phase Two trial here…
Trek, You forget to mention the income over the next few years from EAP which could be substantial and an improved income from the imaging side
Not sure 2.5m for a phase 2 seems v light. Sub 1p CLN’s may help though!
The costs of a Phase 2 trial can vary widely depending on several factors, including the type of study, the number of participants, and the therapeutic area. Based on the provided search results, here are some typical costs associated with a Phase 2 trial:
“Average cost: The average cost of a Phase 2 study in the United States ranges from $7.0 million (cardiovascular) to $19.6 million (hematology).
Clinical procedure costs: These costs account for 15%-22% of the total study costs and can range from $1.4 million to $6.6 million.
Administrative staff costs: These costs account for 11%-29% of the total study costs and can range from $1.4 million to $6.6 million.
Site monitoring costs: These costs account for 9%-14% of the total study costs and can range from $1.4 million to $6.6 million.
Number of participants: The number of participants in a Phase 2 trial can vary widely, but typically ranges from 100 to 300 participants.
Cost per participant: The cost per participant in a Phase 2 trial can range from $20,000 to $60,000 or more, depending on the study design and therapeutic area”
So FoS TB reckons he can do it for pretty much the existing admin costs over 3 years! What a load of bllx!
Usual caveats
Trek
Started: BertieBassett, 14 Jun 2024 08:47
Last post: BertieBassett, 14 Jun 2024 08:47
Firm costs are currently being determined but are projected between $2 - $2.5 million over the duration of the trial which is expected to commence in 2025. IQAI anticipates making a significant contribution to the costs of the Phase 2 trial, in combination with possible grants and further support from charitable foundations if necessary. We had previously expected to seek a partner for this stage of development but now believe that it would better commercially to continue in a proprietorial role during phase 2.
Started: BertieBassett, 11 Jun 2024 10:24
Last post: xviolet, 13 Jun 2024 08:14
Where should I look?
I looked at the FAB website - lots of books. Glanced at filings - I'm 2 ignorant re accountancy to comprehend them. But there is something else?
That aside it is usually considered a good thing if the BOD own a lot of stock.
Do some research into FAB. It's like watching an episode of X Factor ... in which every performance is worse than the last ...
Eyebrow raising and quite irksome ...
-- BB --
Started: The_Paladin, 7 Jun 2024 09:43
Last post: cl81227, 11 Jun 2024 11:56
0.8 he'll be lucky. 10.8 and I might think about it !!
Sorry Linandy, reread my post, it was not meant to come across as an accusation.
Actually I done one sell last week red
If our suspicions become reality, then yes, I’m speechless. I’m so in the red that I can’t sell. I appreciate the risks associated with investments but a share to be brought down not because of the technology, but greed of the board is well… appalling. If I break even one day, then I’ll be content! But doubt that will happen.
I’ve not hid the fact just peed off with how TB has taken lths for idiots just wish I’d gone with my gut 18 months ago good luck to you
If it is FAB (or TB) selling when do they have to inform the markets if they are currently at 8.87% (20.64%)?
I hope that isn’t the case but somebody is definitely getting rid of a few shares. We are due a shareholder letter soon, hopefully that has some good news in it. Maybe first patients enrolled on EAP etc
Thanks
Started: Kaneonaim, 7 Jun 2024 17:17
Last post: Tyke68, 7 Jun 2024 19:57
I wonder if we still have our South Korean distributors and how many sales they have done in 5 years?
https://www.imagingbiometrics.com/2019/03/28-nov-2018-3/
You never hear of sales in the Asian market, that would have been a nice revenue stream.
Thanks
AJNR Scantastic - Dr. Lea Alhilali creatively takes the confusion out of tumor perfusion.
https://www.youtube.com/watch?v=aFZvO6PeWeA
Last post: maximillion69, 6 Jun 2024 21:44
Thanks Kaneonaim
Great find
The objective of this program is to provide GaM for compassionate use in patients with relapsed/refractory histologic or molecular glioblastoma who have exhausted available treatments.
The population of this program is adult patients aged greater than or equal to 18 years with a diagnosis of relapsed/refractory histologic or molecular glioblastoma, according to the WHO 2021 diagnostic criteria.
Molecular glioblastoma is characterized as an IDH-wildtype diffuse and astrocytic glioma in adults if there is microvascular proliferation or necrosis or TERT promoter mutation or EGFR gene amplification or +7/-10 chromosome copy number changes
Full description
This is an intermediate-sized expanded access treatment protocol. GaM (GaM) will be provided as 500 mg capsules and will be self-administered once daily by mouth at the assigned dose level on a 28-day cycle (one cycle is 28 days). Initially, the patients will be provided a three (3) cycle prescription (a 28-day supply with two refills); enough total supply of GaM for three full cycles to allow for self-administration at home. It should be taken on an empty stomach. After that initial period, subsequent GaM will be provided to patients for continued self-administration.
At the treating physician's discretion, additional medication(s) may be administered. Clinical use of cancer-supportive care therapies is unrestricted, but the non-emergent use of additional anti-cancer therapies requires prior consultation with xCures and Imaging Biometrics. xCures along with Imaging Biometrics will be consulted prior to the non-emergent administration of any additional anti-cancer medications. xCures, along with Imaging Biometrics, should be consulted prior to any schedule modifications or the addition of other therapy. The patients may discontinue therapy at any time for any reason. The treating physician can discontinue therapy with GaM at any time for any reason.
https://ctv.veeva.com/study/expanded-access-to-gallium-maltolate-gam
https://clinicaltrials.gov/study/NCT06404034?tab=history&a=1#version-content-panel
I see that there have been various data releases at ASCO '24 in the US over the weekend., It's one of the largest and most prestigeous cancer conferences in the world and a good announcement does wonders for a company's SP. If we ever get the RNS confirming that the good doctor is preaeneting at ASCO 25, its would be very good news...
It looks like we are entering a period of just drifting along. No news, no big transactions. A long wait until we hear about end of phase 1 and start of phase 2.
Thanks
Started: maximillion69, 1 Jun 2024 07:37
Last post: maximillion69, 3 Jun 2024 17:46
3.3M mkt cap, plenty of upside here.
Thanks all,
Plenty to think about. The EAP makes sense as one, the other is the mystery.
Cheers
Shrek
Dr. Connelly answers a question on the phase 1 status at around the 30 minute mark in the this presentation.
https://youtu.be/QgzE34enGj0
Primary Outcome Measures :
1. Maximum-tolerated dose. [ Time Frame: Each 28-day cohort ]This will be determined from the incidence of dose limiting toxicities at each dosage.
From half year report August 2023
The amendment will expand the targeted enrolment from 24 to 36 subjects and allow for continued dose escalation. The MTD determined in Phase 1 will define the "recommended phase II dose" (RP2D) that will be used in the Phase 2 trial. This amendment is the fastest and most efficient way to satisfy the primary goal of the Phase 1.
Given the expanded target enrolment and assuming the strong momentum in patient enrolment continues, it is anticipated that Phase 1 will close in 2024. After enrolment closes, the last patients enrolled will remain on the trial until all required study data is collected. Analysing the data and documenting the phase 1 results is expected to be completed in the second half of 2024.
While the MTD is being determined in the final stages of Phase 1, the clinical team will complete the Phase 2 protocol. The Phase 2 trial is designed to evaluate preliminary evidence of efficacy. Ideally, the Phase II trial will open for patient recruitment in early 2025. This will be a multi-centre trial with a tentative target enrolment of approximately 65 patients over a three-year duration. The design of the Phase 2 study is currently being defined. Factors such as the Phase 1 results and whether the study will be a comparison to historical controls or if it will be randomized (comparing patients with standard treatment alone against those receiving standard treatment with GaM) will influence the overall scope and cost.
The multi-site Phase 2 trial will require new funding which we anticipate will come substantially from a partnership arrangement with a large pharmaceutical company and grants, including those from charitable foundations and other institutions. We anticipate publishing frequent updates to our shareholders as developments unfold.
From 13 October 2023
letter to shareholders
Our sponsored phase 1 clinical trial of oral gallium maltolate (GaM) has increased momentum since it opened in March of 2022. Patients enrolled and were prescribed escalating doses of the agent per the trial's design with the primary goal of identifying the maximum tolerated dose (MTD) for a phase 2 trial. Because patients have tolerated the agent so well, an amendment to the trial's IND had to be written and has since been approved to allow subjects to be administered higher dose levels. This is because the patients have tolerated the initial doses of the agent extremely well and a phase 2 trial requires that a MTD be determined. This dose escalation corresponds to an increase of subjects from 24 to 36. As soon as the MTD is determined, enrollment for the phase 1 trial will halt, data will be summarised, and focus will shift for the commencement of the phase 2 trial.
Started: Kaneonaim, 2 Jun 2024 10:19
Last post: Tyke68, 2 Jun 2024 10:23
Kane
Great find
Thanks
In recent months I have received several requests for information on gallium maltolate in the treatment of glioblastoma and so with the help of a volunteer, Mario Iannaccone who took an interest and studied the topic in depth, I decided to write this article.
We all know that glioblastoma multiforme (GBM) is known for its poor prognosis and poor long-term survival. In recent decades, progress in treatment has been limited, with the Stupp protocol, which combines surgery, temozolomide (TMZ) and radiotherapy, remaining the standard of care. However, a new frontier in research may offer unexpected hope: gallium maltolate.
Gallium maltolate is a promising compound in the treatment of glioblastoma. Wisconsin College of Medicine professor Jennifer Connelly has led numerous studies, indicating the potential of this compound in the treatment of GBM. But why gallium? Gallium, similar to iron in the periodic table, can “trick” tumor cells that require iron to grow, entering the cells through transferrin receptors and disrupting vital tumor processes.
Preclinical studies have shown that gallium maltolate taken orally effectively inhibits the growth of glioblastoma by targeting iron metabolism in tumor cells. Experiments on tumor cells and animal models have shown that gallium maltolate can significantly reduce the growth of GBM. In preclinical studies, glioblastoma cells treated with gallium showed a reduction in tumor volume and growth rate.
In 2022, the first phase 1 clinical trial of gallium maltolate for recurrent glioblastoma was launched. Preliminary results have been encouraging, showing not only good tolerability of the drug but also potential efficacy in reducing tumor size. In addition, the Food and Drug Administration (FDA) recently granted orphan drug designation to gallium maltolate for the treatment of relapsed and refractory glioblastoma.
https://www.glioblastomamultiforme.it/en/gallium-maltolate-a-new-hope-in-the-treatment-of-glioblastoma/
Last post: BertieBassett, 30 May 2024 14:25
100% Trek, 100%
-- BB --
100% Trek, 100%
-- BB --
No matter how they arrived at these figures cos they don’t make any sense, surprise! Perhaps shthouse counted them!
Even on their own numbers 15.4% voted for the CEO to be ousted! That is a serious kick in the gonads!
As you can tell from the subsequent CEO shareholder engagement. The live meetme, the updated corporate PowerPoint explaining their strategy, the proactive interviews and the revamped website from the crock of sht it currently is TB is serious about making amends!
Shareholders should do some serious research before giving their hard earned to this guy!
Usual caveats
Trek
Please share good old Bertie
Started: Tyke68, 24 May 2024 13:08
Last post: Tyke68, 30 May 2024 11:05
Well I guess it has just stayed the same
Thanks
Reported use in another clinical trial.
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial
Published: 28 May 2024
Nature Communications 15, Article number: 4210
This is the link:
https://www.nature.com/articles/s41467-024-48416-9
“All image post-processing and interpretation were performed using IB NeuroTM (Imaging Biometrics), Olea Sphere (Olea Medical), and Mint LesionTM (Mint Medical GmbH) software and assessed by a central reader not involved in the treatment of the patients (SB). MRI response values for all patients can be found in Supplementary Data 4”.
Study locations in Germany
Shrek
Global Market Access Manager , Radiology Bayer
https://www.linkedin.com/posts/prateek-bharadwaj-70527955_ai-has-firmly-established-its-presence-in-activity-7181592308830650368-7zPz?utm_source=share&utm_medium=member_ios
Not sure if already posted
Thanks Max
This bit is the key bit for me
“As part of our efforts, we have collaborated with several AI leaders in the neurology field, including Combinostics, Imaging Biometrics, LLC and Cercare Medical,”
So we are regarded as AI leaders!
Combinostics are Finnish and Cercare are Danish companies, I can’t find any valuations for them
Thanks
Started: Cautious11, 24 May 2024 13:35
Last post: Cautious11, 24 May 2024 13:35
Someone is suppressing the share price. If it’s the crooks then they dont need to sell many go to keep it were it is or lower.
Never think Brown or his cronies are doing you a favour.
I can see Cln’s coming, and he will keep them for 2 years which will keep hovering over the share price
If he has any decency at all and raises a Cln do it at 2.5 or 3p and show your faith in the company and not the greedy CEO you portray
Last post: TrekMadone, 23 May 2024 19:38
It’s another good development but against the recent backdrop people of sceptical that it’s paving the way for cash.
No numbers, no sales team in place. Look at how hard ONC have to work in US and Europe to sell diagnostics! That’s with 5 full time reps!
At the end of the day it’s an app that has loads of potential but is still in development.
TB has a choice to raise cash and go it alone or bring someone in to finance it or buy it outright.
They are doing amazingly well on a shoestring but soon choices have to be made and investors will sit until there is clarity.
Shame cos it needn’t have been like that. I for one would have backed him had he an ounce of integrity!
Still in purgatory TB. Proactive await your call!
Usual caveats
Trek
Well I think the answer to my question morning, will the RNS raise the sp” is a resounding no.
We need something to get the momentum going. I hate to think how high this could have been with the last 5 RNSs if it had started from the New Year 5p price.
Just remember the last Crystal research from August was hoping for 6.5p. We need something to kickstart the rise again. Something major hopefully. A JV, takeover, sale of the imaging side etc..
Fingers crossed
Thanks
RNS OUT
Let’s see if today’s good news RNS increases the sp?
Thanks
FDA cleared in 2008🤷♂️what does it take to make any money from this stuff.
Started: Tyke68, 23 May 2024 11:26
Last post: xviolet, 23 May 2024 12:52
Nice work Kane
And good to hear that Nimble has legs - whenever the IB team take on something new it seems to go well.
Beyond that...not much to say.
MMM
Hopefully some people can
Let’s see what happens
Thanks
Tyke68, we need someone to go to AGM. Unfortunately I live in Mumbai atm, so cant attend
The one thing I think we need to know from the AGM is how the board intend to increase the share price. The recent flood of great RNSs has had no effect.
I know things have happened in the past but what is going to be done now to have a positive effect? Directors buying more shares maybe? What are they planning moving forward. We need a bit of impetus then hopefully it will keep going.
Thanks
Last post: cl81227, 23 May 2024 11:00
I think if all our mystery guest Elartu is concerned about with IQAI, is data protection, then I can safely advise, this share isn't for him and he would be safer taking his investment, assuming he has one elsewhere.!!
Is a troll from feedback plc obviously bitter that Trevor their ex director has developed a better app than their app bleepa lol!! And for less than half the cost!!
Started: Cautious11, 23 May 2024 07:59
Last post: steve124, 23 May 2024 10:22
Elartu - apologies this is not strictly speaking related to IQAI but about data security you worry about.
Within the last year, I lost my wife of 27yrs and she spent the last year of her life in hospital before she passed. The nurses there had a hospital ipad and they took photos each week of her bedsores which were getting continually worse. When someone was really concerned they called the top nurse down 9she had a red uniform and had her own office) she agreed they were unacceptable but then took some photos from a phone she pulled from her own pocket. She admitted it was her own private phone but would only forward the pics to the same place the ipad ones were stored. Point I'm probably not making very well is that I know what she did broke every data law ever written but her intentions were honourable. You can put as many rules or procedures in place you want but if someone is very busy they will always find a quicker way regardless of the rules - or not do the task at all because of all the hurdles.
Sorry for the ramble.
LIMITATION OF LIABILITY
Under no circumstances, including, without limitation, negligence, shall IB or its parents, subsidiaries, affiliates, officers, directors, employees, agents, or suppliers be liable for any direct, indirect, incidental, special or consequential damages arising from or in connection with the use of or the inability to use this Site or any content contained on the Site, or, except as otherwise provided under applicable laws and regulations regarding the security of personal data, resulting from unauthorized access to or alteration of your transmissions or data, or other information that is sent or received or not sent or received.
INDEMNIFICATION
You agree to indemnify, defend, and hold IB and IB’s affiliates, business partners, officers, directors, employees, and agents harmless from any loss, liability, claim, action, suit, demand, damage, or expense (including reasonable legal fees, costs of investigation and court costs) asserted by any third party relating in any way to, or in respect of, your use of the Site, any third party applications, software, or content you post or share on or through the Site, or breach of these Terms of Use. IB reserves the right to assume the exclusive defense and control of any matter subject to indemnification by you, which shall not excuse your indemnity obligations.
LINKS AND THIRD PARTY CONTENT
The Site also provides links to other sites, such as professional organizations and sales partners. While we try to link only to sites that share our high standards, the content and privacy standards of these other sites is beyond our control. These sites and their related content may set third party cookies over which we do not have access or control. The use of cookies by third parties is not covered by our Privacy Policy.
DISCLAIMER
This Site and the Content available through it are provided on an “as is” and “as available” basis.
To the fullest extent permissible pursuant to applicable law, IB and its affiliates disclaim all warranties of any kind, whether express or implied, including without limitation any warranty of merchantability, fitness for a particular purpose or non-infringement.
You expressly agree that any use of this site, including all content, data or software distributed by, downloaded or accessed from or through the site, is at your sole risk. You understand and agree that you will be solely responsible for any damage to your business, your computer system or loss of data that results from the download of such content, data and/or software.
IB does not make any warranty that this Site or its Content will meet your requirements, or that this Site or its Content will be uninterrupted, timely, secure, or error free, or that defects, if any, will be corrected, nor does IB make any warranty as to the results that may be obtained from use of this Site or its Content or as to the accuracy, completeness or reliability of any information obtained through use of this Site. Except as otherwise provided under applicable laws and regulations regarding the security of personal data, IB disclaims any warranty or representation that confidentiality of information transmitted through the site will be maintained.
No advice or information, whether oral or written, obtained by you from IB or third parties through the site shall create any warranty. Some jurisdictions do not allow the limitation or exclusion of certain warranties or conditions, so some of the above exclusions may not apply to you.
All content on this Site, including but not limited to design, text, software, technical drawings, configurations, graphics, other files, and their selection and arrangement (“Content”), are either the property of IB. All rights reserved.
The Contents of the Site may not be modified, copied, distributed, framed, reproduced, republished, downloaded, displayed, posted, transmitted, or sold in any form or by any means, in whole or in part, without IB’s prior written permission, except that you may download and print content for uses that are not competitive with or derogatory to IB, provided that you keep all copyright or other proprietary notices intact.
TRADEMARKS
All trademarks on the Site are either trademarks or registered trademarks of IB or its affiliates or licensors and may not be copied, imitated, or used, in whole or in part, without the prior written permission of IB. All page headers, custom graphics, icons, and scripts are service marks, trademarks and/or trade dress of IB, and may not be copied, imitated, or used, in whole or in part, without the prior written permission of IB. Other trademarks, registered trademarks, product names, and company names or logos displayed on the Site are the property of their respective owners.
PATENTS
IB’s products and processes are covered by patents and are subject to other trade secret and proprietary rights. IB reserves all such rights. No transfer or grant of rights under any patents is made or is to be implied by any provision of these Terms of Use. You agree not to infringe upon such rights or decompile, reverse engineer, or disassemble any of IB’s products or processes.
PRIVACY PROTECTION
You acknowledge and agree that IB may use the data collected in the course of our relationship for the purposes identified in our Privacy Protection.
Content, Product and Service Information – Limitations
All content available through the Site, including but not limited to data, technical drawings, configurations, quote and order information, and catalog listings is believed to be accurate. However, you should independently evaluate the accuracy of the information and the usefulness for your particular needs of any content, product or service available through the Site. Specifications for products and services are subject to change without notice, and IB reserves the right to make changes without notice to processing, materials, or configuration. All information on the Site is subject to the below disclaimer section.
POLICIES
Imaging Biometrics, LLC, an IQ-AI company, shares your concerns regarding internet privacy. We think you should know how we treat the information that we receive from you, and have created this statement of our policy to demonstrate our continued commitment to privacy.
IQ-AI, Ltd is registered in Jersey 2044 with offices at P. O. Box 264, Forum 4, Grenville Street, St Helier, Jersey Channel Islands, JE4 8TQ.
PRIVACY PROTECTION POLICY
Personal Data Collection and Use
Imaging Biometrics (IB) does not require users to disclose personal information, such as name, address, e-mail address and occupation. However, in order to obtain specific information, documents, or trials of our software, you may have to register and provide certain personal data. IB hereby informs you that all such personal data you may provide online are intended for use solely by IB to further discuss client/partner interest in our products and services. Such data shall not be disclosed to third parties other than third parties hired by IB to host or manage the Site. Third parties are required to maintain the confidentiality of said data and are prohibited from using the data for any purpose other than the operation or management of the Site. IB agrees to take all such reasonable measures as may be available to it in order to ensure the confidentiality of said personal data. You have the right to oppose, access and correct such personal data. You may exercise this right at any time by sending a request in writing to:
Imaging Biometrics, LLC
13416 Watertown Plank Road, Ste #260
Elm Grove, WI 53122 USA
info@imagingbiometrics.com.
Any related changes or deletions will be made as soon as reasonably practicable and in any event, no later than five working days following receipt of your notice.
INFORMATION IB DOES NOT COLLECT
IB does not intentionally collect sensitive personal information, such as social security numbers, ethnicity, genetic data, health information, or religious affiliation.
TERMS OF USE
These Terms of User (Terms) may be changed from time to time and without further notice. Your continued use of the Site after any such changes constitutes your acceptance of the new terms. If you do not agree to abide by these or any future terms, please do not use the Site or download materials from it.
IB may terminate, change, suspend or discontinue any aspect of the Site, including the availability of any features, at any time. IB may remove, modify or otherwise change any content, including that of third parties, on or from this Site. IB may impose limits on certain features and services or restrict your access to parts or all of the Site without notice or liability. IB may terminate your use of the Site at any time in its sole discretion.
Copyrights
All content on this Site, including but not limited to design, text, software, technical drawings, configurations, graphics, other files, and their selection and arrangement (“Conten
Thy are all out this morning, are the schools closed today?
Started: BertieBassett, 23 May 2024 08:49
Last post: BertieBassett, 23 May 2024 08:49
In IB, we trust.
In IQ, we don't.
-- BB --
Started: BertieBassett, 20 May 2024 09:08
Last post: steve124, 21 May 2024 18:53
Bertie - they are not an American company?
The Fifth Amendment also protects criminal defendants from having to testify if they may incriminate themselves through the testimony. A witness may "plead the Fifth" and not answer if the witness believes answering the question may be self-incriminatory.
Tyke,
Yes - he was! 2014 - 2017.
Strange that all his entities have used Peterhouse.
Also, Peterhouse refuses to engage in any dialogue ... I wonder why ...
-- BB --
I have just noticed TB used to be a director of Peterhouse. Coincidence?
Thanks
Loizos Siakallis is based at UCL London so that could be a foothold into the NHS. The NHS say they want to use AI, wouldn’t it be nice if they ensured all their scanners used our technology. The word keeps spreading, unfortunately the more good news we have the more decrease in our sp. Negative correlation and I didn’t have to use AI to work that out.
Thanks
Another group (Siakallis, et al) presented at ASNR in Las Vegas showed that choosing IB Neuro’s standardized and leakage corrected rCBV is best when developing AI algorithms to identify molecular marker status
Last post: xviolet, 20 May 2024 22:38
What is that expression?
'the patience of a saint'.
that means it is a quality that (us) normal people do not have. that is very interesting.
Last post: Cautious11, 20 May 2024 09:22
Initially the PRD’s were finishing in 2020 so there was a rush from companies to get on the list. That year the FDA accepted 221 PRD,s, With it finally coming to an end this September I’m sure there will be another rush. Now put that against how few PRV’s are giving out against PRD’s it’s a very small number. The last chance to achieve a PRV is end of 2026
The sooner a large company comes along to push this through the better for all of us if achievable at all
Tyke,
I see your point - I really do.
All drug companies strive to make the world a better place and for that they should be celebrated.
BUT we get kicked so often by IQAI surely we would want these amazing drugs to be protected by a company with moral & ethical terpitude?
For IQAI it's about the money. Pure & simple. Roll-on a takeover ...
In IB I believe - in IQAI I don't.
-- BB --
Thanks Tyke68
Everybody is now only looking for the negatives with this share. Why not think of the positives of how it can possibly help children with a terrible disease.
I understand the distrust of TB so play him at his own game, sell on the rise and buy on the fall. Or are people worried we may get a transformational RNS and they miss out, I don’t know?
Me personally I would say the company is now ripe for a takeover, ODD, EAP, fast track, PRDD plus the imaging side.
Tax breaks, exclusivity, two PRVs, possibly worth $200m plus, phase 1 about to be completed successfully.
Let’s remember how all this has been achieved with so little funding
A big congratulations to all the team, keep up the great work.
I know this post may upset some but I far prefer to think positively rather than negatively and all the good the team are contributing to healthcare.
Have a good week
Thanks
Started: Cautious11, 20 May 2024 08:05
Last post: maximillion69, 20 May 2024 08:33
Cynical me thinks why an Rns at 7.10 rather than the normal 7.00 time. This news had to be an , so was he hoping it would not be noticed so to keep the price down